Six top tips to prepare for the new EU Clinical Trial Regulation

The European Union Clinical Trial Regulation 536/2014 (EU-CTR) aims to standardize and harmonize the conduct and management of interventional clinical trials across the European Economic Area (EEA), with legally binding rules on requirements and increased transparency. The new EU-CTR promises a simplified process designed to decrease the burden resulting from idiosyncratic interpretations of the current EU-CTD. But to reap efficiencies, sponsors must sow operational changes. This article covers the six essential preparations companies should undertake now.


Open PDF

Return to Insights Center

Related Insights

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Blog

Biosimilar Development: Are therapeutic clinical trials needed?

Nov 16, 2021

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

How emerging biotechs can enter the Chinese market and prosper

Jan 18, 2022

Video

Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022